Dr. Gregory Stock is a leading authority on the broad impacts of genomic and other advanced technologies in the life sciences. He was the co-founder and CEO both of Signum Biosciences, a Princeton-based biotechnology company developing therapeutics for Alzheimer’s and other neurodegenerative diseases, and of Ecoeos, an innovative genomics company offering genetic tests for susceptibility to environmental toxins. He also was the founder and Director of the Program on Medicine, Technology and Society at UCLA’s School of Medicine where he explored critical technologies poised to impact humanity’s future and the shape of medical science and to catalyze broad public debate about their implications for public policy. A focus of his was on the implications for healthcare of today’s revolution in molecular genetics and bioinformatics.
Dr. Stock’s book, Redesigning Humans: Our Inevitable Genetic Future with Houghton Mifflin, won the Kistler Book Prize for Science books and was nominated for a Wired Rave Award. Among his other books are Engineering The Human Germline for Oxford University Press, Metaman, for Simon & Schuster, and the best seller, The Book of Questions, which has been translated into eighteen languages and is now in its sixty-seventh printing. Sequels to that book include The Book of Questions: Business, Politics, and Ethics and a new book that will explore how coming technologies will reshape our everyday lives. Dr. Stock sits on the editorial board of the American Journal of Bioethics, The Journal of Evolution and Technology, and Rejuvenation Research.
He makes regular appearances on television and radio, including CNN, PBS, NPR, Bloomberg and the BBC and has debated biotech policy with Jeremy Rifkin, Leon Kass, Francis Fukuyama, Bill McKibben and other prominent policy figures. He serves on the California Advisory Committee on Stem Cells and Reproductive Cloning, and is the Associate Director of the BioAgenda Institute, a policy think tank at UC Berkeley. He has a Ph.D. in Biophysics from Johns Hopkins University and an MBA from Harvard University.